Pathogenesis of Cardiotoxicity Induced by Anthracyclines
Author:
- 1 June 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 2-7
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- La cardiotoxicité des anthracyclines : mécanismes et cibles pharmacologiques de prévention2004
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphomaAnnals of Oncology, 2003
- Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patientsAnnals of Oncology, 2002
- Tailored Therapy to Hemodynamic Goals for Advanced Heart FailureEuropean Journal of Heart Failure, 1999
- Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.Journal of Clinical Oncology, 1998
- Doxorubicin-induced congestive heart failure in adultsCancer, 1985
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemiaCancer, 1967